HOTH Hoth Therapeutics Inc.

2.89
+0.05  (+2%)
Previous Close 2.84
Open 2.9
Price To Book 6.88
Market Cap 33,528,933
Shares 11,601,707
Volume 634,695
Short Ratio
Av. Daily Volume 608,790
Stock charts supplied by TradingView

NewsSee all news

  1. The Benchmark Company Announces Closing of Public Offering of $5.0 Million for Hoth Therapeutics, Inc.

    NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company announced the closing on March 27th of an Underwritten Public Offering for Hoth Therapeutics, Inc. (NASDAQ:HOTH) of 1,818,182 shares of common stock at a

  2. Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board

    NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters

  3. Hoth Announces Pricing of Public Offering of Shares of Common Stock

    NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of

  4. Hoth Announces Proposed Public Offering of Common Stock

    NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in

  5. Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic

    NEW YORK, May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data expected by the end of 2020 or early 2021
BioLexa
Atopic Dermatitis

Latest News

  1. The Benchmark Company Announces Closing of Public Offering of $5.0 Million for Hoth Therapeutics, Inc.

    NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company announced the closing on March 27th of an Underwritten Public Offering for Hoth Therapeutics, Inc. (NASDAQ:HOTH) of 1,818,182 shares of common stock at a

  2. Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board

    NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters

  3. Hoth Announces Pricing of Public Offering of Shares of Common Stock

    NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of

  4. Hoth Announces Proposed Public Offering of Common Stock

    NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in

  5. Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic

    NEW YORK, May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University

  6. Voltron Therapeutics Publishes Letter to Shareholders

    NEW YORK, May 19, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announces today a letter to the shareholders. Dear Voltron Therapeutics shareholders, We hope this letter finds you well during this remarkable time. We

  7. Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

    NEW YORK, May 18, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform,

  8. Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.

    NEW YORK, May 5, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö").

  9. Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine

    NEW YORK, April 24, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal

  10. Hoth Therapeutics, Inc., Voltron Therapeutics, Inc., & HaloVax Announce Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine

    NEW YORK, April 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and

  11. REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate

    NEW YORK, April 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23,

  12. Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate

    NEW YORK, April 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23,

  13. Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study

    NEW YORK, April 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin

  14. Hoth Therapeutics Announces Additions to its Board of Directors

    NEW YORK, April 17, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board

  15. Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines

    NEW YORK, April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform,

  16. Hoth Therapeutics Commences Next Phase of VNLG-152 Study

    NEW YORK, April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism

  17. Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)

    NEW YORK, April 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored

  18. Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases

    NEW YORK, March 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene

  19. HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection

    NEW YORK, March 27, 2020 /PRNewswire/ --  HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc

  20. Hoth Announces Pricing of $5 Million Public Offering of Common Stock

    NEW YORK, March 24, 2020 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced the pricing of its previously announced "best

  21. Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

    NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in

  22. Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)

    NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture

  23. Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss

    NEW YORK, March 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from

  24. Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share

    NEW YORK, March 16, 2020 /PRNewswire/ -- Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has released a comprehensive update note of Hoth

  25. Hoth Therapeutics, Inc. States COVID-19 Coronavirus Poses No Negative Effect on Company's Operations

    NEW YORK, March 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from

  26. Hoth Therapeutics Receives Notice of Allowance from European Patent Office

    NEW YORK, Feb. 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from

  27. Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

    NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from

  28. Hoth Therapeutics, Inc. to Present at 2020 Noble Capital Market's Sixteenth Annual Small-Cap Investor Conference

    NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from

  29. Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation

    NEW YORK, Feb. 4, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from

  30. Hoth Therapeutics to Further its Research of VNLG-152 and Plans Exercise of its Option Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.

    NEW YORK, Jan. 29, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic

  31. Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

    NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic

  32. Emerging Markets Report: A Very Big Deal

    ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- It doesn't take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn't take any research firm

  33. Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects

    NEW YORK, Jan. 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from

  34. Emerging Markets Report: Acne, Eczema, and Asthma

    ORLANDO, Fla., Jan. 14, 2020 (GLOBE NEWSWIRE) -- The headline of our written offering today probably appears a little different from our regular titles. Typically we don't lead with things that are so widely despised

  35. Hoth Therapeutics, Inc. Issues 2019 Shareholder Letter

    NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and

  36. Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression

    NEW YORK, Dec. 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological

  37. Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board

    NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological

  38. Emerging Markets Report - Hoth Therapeutics on the Fast Track Toward Delivering Eczema Therapy Products to Market

    ORLANDO, Fla., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Nearly every person suffering from atopic dermatitis, more popularly known as "eczema," knows just how difficult it can be to find effective remedies for his or her

  39. Hoth Therapeutics, Inc. to Present at the Investor Summit on December 17th in Philadelphia

    PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), will be presenting at this year's Investor Summit on December 17th in Philadelphia.The Investor Summit will take place at

  40. Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma

    NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological

  41. Hoth Therapeutics to Present at the LD Micro Main Event (XII)

    NEW YORK, NY / ACCESSWIRE / December 2, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for

  42. Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy

    NEW YORK, Nov. 26, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological

  43. Hoth Therapeutics to Attend Benchmark's 8th Annual Discovery 1x1 Conference

    NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological

  44. Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological

  45. Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from

  46. Hoth Therapeutics to Present at the Dawson James 5th Annual Small Cap Growth Conference

    NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also

  47. Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month"

    NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also

  48. Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also

  49. Emerging Markets Report: Looking Beyond Skin Deep

    ORLANDO, Fla., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Today's featured company Hoth Therapeutics, Inc. (NASDAQ:HOTH) makes its claim in the marketplace of Life Science ideas with an array of skin-related products that span

  50. Hoth Therapeutics, Inc. to Present at Diamond Equity Research Emerging Growth Invitational

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also

  51. Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

    NEW YORK, Sept. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also